🔍

ASTRAZEN - Astrazeneca Phar

📊 NSE: ASTRAZEN 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/13/2025 18:40

📢 Recent Corporate Announcements

AstraZeneca Pharma India to Close Trading Window from March 16, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Mar 2026, 05:01 PM

AstraZeneca Pharma India Limited has announced the closure of its trading window for equity shares starting March 16, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's upcoming financial disclosures. The window will remain closed until 48 hours after the declaration of the audited financial results for the quarter and year ending March 31, 2026. This is a standard regulatory procedure to prevent insider trading during the period when price-sensitive information is being finalized.

Trading window for dealing in Equity Shares will be closed from March 16, 2026.
Closure is related to the upcoming audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
The announcement is made pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should monitor the upcoming earnings release for actual performance data.

AstraZeneca Pharma India Appoints Sandhya Tejaswini Amanna as Director - Legal

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 11 Mar 2026, 04:39 PM

AstraZeneca Pharma India Limited has appointed Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. Mrs. Amanna is a seasoned professional with over 20 years of experience in the legal, compliance, and governance sectors across pharmaceutical and FMCG industries. She joins the company from Danone India, where she served as the Head of Legal, Compliance, and Secretarial. Her extensive background in intellectual property litigation and legal risk management is expected to strengthen the company's internal governance frameworks.

Appointment of Mrs. Sandhya Tejaswini Amanna as Director - Legal effective from March 18, 2026.
The appointee brings over 20 years of professional experience in manufacturing, FMCG, and pharmaceutical sectors.
Previously served as Head of Legal, Compliance, and Secretarial at Danone India.
Expertise includes end-to-end contract management, IP litigation, and legal risk management.
The appointment was approved by the Board based on the recommendation of the Nomination and Remuneration Committee.

💡 This is a routine senior management appointment and does not require any immediate portfolio action. Investors should view this as a move to strengthen the company's legal and compliance leadership.

AstraZeneca Pharma India Seeks Approval for ₹3,900 Cr Related Party Transactions

🟡 NEUTRAL ⭐ 7/10

REGULATORY 📅 27 Feb 2026, 04:56 PM

AstraZeneca Pharma India Limited has issued a postal ballot notice to seek shareholder approval for material related party transactions (RPT) for the 2026-27 fiscal year. The company proposes transactions worth up to ₹2,400 crore with AstraZeneca UK Limited and up to ₹1,500 crore with AstraZeneca AB, Sweden. These transactions cover the purchase, transfer, or receipt of products, goods, and services essential for operations. The e-voting period is scheduled from February 28 to March 29, 2026, with results expected by March 31, 2026.

Proposed transactions with AstraZeneca UK Limited capped at ₹2,400 crore for FY 2026-27.
Proposed transactions with AstraZeneca AB, Sweden capped at ₹1,500 crore for FY 2026-27.
Total value of material related party transactions under consideration is ₹3,900 crore.
E-voting period runs from February 28, 2026, to March 29, 2026.
Transactions include purchase of products, goods, materials, and reimbursement of transfer price or other obligations.

💡 Investors should monitor the voting results and review the explanatory statement to ensure these large-scale transactions with parent entities are conducted at arm's length.

AstraZeneca Pharma India Submits SEBI Regulation 74(5) Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 19 Feb 2026, 06:03 PM

AstraZeneca Pharma India Limited has filed a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by the company's Registrar and Transfer Agent, Integrated Registry Management Services, confirms the processing of dematerialization requests. It verifies that physical share certificates were cancelled and the depository's name was updated in the company's records. This filing is a mandatory administrative procedure for listed companies in India to maintain accurate electronic shareholding data.

Submission of compliance certificate for SEBI (Depositories and Participants) Regulations, 2018.
Confirmation provided by Registrar and Transfer Agent, Integrated Registry Management Services Private Limited.
Certificate dated February 5, 2026, ensures the integrity of the dematerialization process.

💡 This is a routine administrative update with no impact on company fundamentals; no action is necessary for shareholders.

AstraZeneca Pharma India Assigned ESG Rating of 70 by NSE Sustainability

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 18 Feb 2026, 03:33 PM

AstraZeneca Pharma India Limited has been assigned an Environmental, Social, and Governance (ESG) rating of 70 by NSE Sustainability Ratings & Analytics Limited. This rating is based on publicly available information pertaining to the financial year 2024-25. The company clarified that it did not formally engage the agency, and the report was prepared independently. This disclosure is in compliance with the latest SEBI mandates regarding ESG reporting for listed entities.

NSE Sustainability assigned an ESG rating of 70 to AstraZeneca Pharma India.
The rating is based on publicly available data for the FY 2024-25 period.
The assessment was conducted independently by the agency without company solicitation.
The disclosure follows SEBI Master Circular requirements dated January 30, 2026.

💡 Investors should view this ESG score as a benchmark for the company's sustainability performance relative to peers. No immediate trading action is required as this is a routine regulatory disclosure.

AstraZeneca India Q3 Revenue Surges 39% to INR 6,115.7 Mn; 8 New Regulatory Approvals Secured

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 07:05 PM

AstraZeneca Pharma India reported a robust 39% YoY growth in total revenue for Q3 FY 2025-26, reaching INR 6,115.7 Mn. The growth was primarily driven by the Oncology segment, which contributed INR 4,395.9 Mn, and Biopharmaceuticals at INR 1,377.4 Mn. The company demonstrated strong pipeline execution with 8 new regulatory approvals over the past nine months, including key indications for Durvalumab and Osimertinib. Profit after tax for the quarter stood at INR 465.4 Mn, supported by consistent performance across all therapy areas.

Total revenue for Q3 FY 2025-26 grew 39% YoY to INR 6,115.7 Mn.
Oncology segment contributed INR 4,395.9 Mn, representing approximately 72% of total quarterly revenue.
Secured 8 new regulatory approvals in 9 months, including treatments for endometrial cancer, MIBC, and rare diseases.
9-month (Apr-Dec '25) total revenue reached INR 16,969.7 Mn with a Profit Before Tax of INR 1,982.3 Mn.
Launched Eculizumab, the first anti-complement therapy in India for rare diseases aHUS and PNH.

💡 Investors should note the strong revenue momentum and the significant expansion of the product portfolio through 8 new approvals. The company's focus on high-value oncology and rare disease segments suggests a positive outlook for long-term margin improvement.

AstraZeneca Pharma India Appoints Tanya Sanish as Company Secretary and Compliance Officer

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 11 Feb 2026, 05:50 PM

AstraZeneca Pharma India Limited has appointed Ms. Tanya Sanish as the Company Secretary and Compliance Officer, effective February 23, 2026. Ms. Sanish is a seasoned professional with over 15 years of experience in corporate governance, capital markets, and M&A transactions. She joins from Piramal Pharma Limited, where she held a similar leadership role, and has previously worked with Pidilite Industries. This appointment is part of the company's effort to maintain robust regulatory compliance and governance standards.

Appointment of Ms. Tanya Sanish as Company Secretary and Compliance Officer effective February 23, 2026.
The appointee brings over 15 years of experience in corporate governance and Indian securities laws.
Previously served as Company Secretary at Piramal Pharma Limited and held positions at Pidilite Industries.
Expertise includes managing high-value fund-raising exercises such as rights issues, QIPs, and debt issuances.

💡 This is a routine management update and does not require any immediate investment action. Investors should view the appointment of an experienced professional as a positive step for long-term governance.

AstraZeneca India Gets CDSCO Approval for Imfinzi in Endometrial Cancer Treatment

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 10 Feb 2026, 10:56 AM

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import and market Durvalumab (Imfinzi) for an additional indication. The drug is now approved for first-line treatment of adults with primary advanced or recurrent endometrial cancer in combination with chemotherapy. This approval covers two dosage forms: 120 mg/2.4 mL and 500 mg/10 mL. This regulatory milestone allows the company to expand its oncology portfolio and address a critical therapeutic area in the Indian market.

Received CDSCO permission to import and distribute Durvalumab (Brand: Imfinzi) for a new indication.
Approved for first-line treatment of primary advanced or recurrent endometrial cancer in combination with chemotherapy.
Available in two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL solution for infusion.
Includes maintenance treatment as monotherapy for mismatch repair deficient (dMMR) endometrial cancer.

💡 This is a positive development that strengthens AstraZeneca's oncology pipeline in India. Investors should monitor the impact on specialty segment revenues in future earnings reports as the product is commercialized for this new indication.

AstraZeneca Pharma India Receives ESG Score of 64.4 (Grade B) from SES ESG Research

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 02 Feb 2026, 06:14 PM

AstraZeneca Pharma India Limited has disclosed its ESG rating as assigned by SES ESG Research Private Limited for FY 2024-25. The company received an adjusted ESG score of 64.4, which corresponds to a Grade B rating. This assessment was conducted independently by SES using publicly available information and was not a paid engagement by the company. The disclosure is in compliance with SEBI's updated regulations regarding ESG transparency for listed entities.

SES ESG Research assigned an adjusted ESG score of 64.4 to the company.
The company achieved a Grade B rating based on data from the 2024-25 financial year.
The rating was unsolicited and based entirely on publicly available information.
Compliance filing follows SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

💡 Investors should note this as a baseline for the company's sustainability performance; while Grade B is stable, focus remains on core pharmaceutical growth and pipeline developments.

AstraZeneca India Gets CDSCO Approval for Imfinzi to Treat Gastric Cancer

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 31 Jan 2026, 01:44 PM

AstraZeneca Pharma India has received approval from the CDSCO to import and market Durvalumab (Imfinzi) for an additional indication in India. The drug is now permitted for the treatment of adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) in combination with FLOT chemotherapy. This approval covers two dosage strengths: 120 mg/2.4 mL and 500 mg/10 mL. This expansion of Imfinzi's therapeutic use is expected to enhance the company's oncology portfolio and addressable patient base.

Received CDSCO permission to import and distribute Durvalumab (Imfinzi) for a new oncology indication.
Approved for treating adult patients with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Permission covers two specific formulations: 120 mg/2.4 mL and 500 mg/10 mL solutions for infusion.
The treatment protocol involves combination with FLOT chemotherapy followed by single-agent Durvalumab.
The approval paves the way for immediate marketing subject to any remaining statutory requirements.

💡 Investors should monitor the commercial launch and uptake of Imfinzi for this new indication as it strengthens the company's high-margin oncology segment. This regulatory milestone is a positive driver for long-term revenue growth in the Indian market.

AstraZeneca Pharma India Non-Executive Director Sylvia Varela Resigns Effective Feb 28, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 29 Jan 2026, 05:05 PM

Ms. Sylvia Lorena Varela Ramon, a Non-Executive Director at AstraZeneca Pharma India Limited, has resigned from her position effective February 28, 2026. She is stepping down to pursue career opportunities outside the organization. Consequently, she will also vacate her roles in the Nomination and Remuneration Committee and the Stakeholder's Relationship Committee. This transition appears to be a routine management change with no negative implications cited in the disclosure.

Resignation of Ms. Sylvia Lorena Varela Ramon as Non-Executive Director effective close of business Feb 28, 2026
Departure includes stepping down from the Nomination and Remuneration Committee
Departure includes stepping down from the Stakeholder's Relationship Committee
Reason cited is to pursue career opportunities outside the AstraZeneca organization
Official notification provided to BSE and NSE on January 29, 2026

💡 No immediate action is required as this is a routine board-level resignation. Investors should monitor for the appointment of a replacement to ensure continued board oversight.

AstraZeneca Pharma Receives Rs 11.88 Crore Final Income Tax Assessment Order

🔵 WATCH ⭐ 4/10

LEGAL 📅 16 Jan 2026, 06:43 PM

AstraZeneca Pharma India Limited has received a final assessment order for the assessment year 2022-23 from the Income Tax Department. The order proposes adjustments related to legacy transfer pricing and corporate tax issues, amounting to approximately Rs. 11.88 crores. This figure excludes additional interest and penalties that may be applied. The company has stated it will challenge this order by filing an appeal before the Income-tax Appellate Tribunal (ITAT).

Final assessment order received under Section 143(3) of the Income Tax Act for AY 2022-23.
Total claim amount is approximately Rs. 11.88 crores excluding interest and penalties.
Dispute pertains to legacy transfer pricing and corporate tax adjustments.
Company intends to contest the order before the Income-tax Appellate Tribunal (ITAT).

💡 Investors should monitor the outcome of the ITAT appeal as it pertains to recurring transfer pricing issues. The current claim amount is relatively small compared to the company's annual revenue, suggesting limited immediate financial risk.

AstraZeneca Pharma India Files SEBI Regulation 74(5) Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 16 Jan 2026, 06:19 PM

AstraZeneca Pharma India Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Integrated Registry Management Services Private Limited, confirms the processing and cancellation of share certificates for dematerialization. This is a standard procedural filing required by SEBI to ensure the integrity of the depository system. There is no impact on the company's financial standing or business operations.

Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 confirmed.
Certificate issued by Registrar and Transfer Agent, Integrated Registry Management Services Private Limited.
Confirmation of dematerialization and cancellation of share certificates as per regulatory standards.
Official filing dated January 16, 2026, following the RTA certificate from January 6, 2026.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's core pharmaceutical business performance and product launches.

AstraZeneca Pharma India Schedules Investor Meetings for January 21, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Jan 2026, 06:18 PM

AstraZeneca Pharma India Limited has announced a schedule for one-on-one interactions with institutional investors and analysts on January 21, 2026. The company will meet with Mr. Satish Bhatt, Mr. Tejas Trivedi, and representatives from ICICI Prudential Asset Management Company Limited. These meetings are scheduled to take place at the company's corporate office in Bangalore. This is a routine disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015.

One-on-one meetings scheduled for Wednesday, January 21, 2026
Interaction with ICICI Prudential Asset Management Company Limited
Individual meetings with analysts Mr. Satish Bhatt and Mr. Tejas Trivedi
Meetings to be conducted at the Bangalore Corporate Office

💡 Investors should monitor the company's website or exchange filings for any investor presentations or transcripts that may be released following these meetings.

AstraZeneca Pharma India Appoints New Directors for Oncology and Institutional Business

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 09 Jan 2026, 11:51 AM

AstraZeneca Pharma India has announced two key senior management appointments effective January 12, 2026, to strengthen its commercial leadership. Ms. Aditi Dayarus Mehta, with over 15 years of experience from Pfizer and BMS, joins as Director of the Oncology Business Unit. Mr. Nitin Bindal, an IIT Bombay and UCLA alumnus with 17 years of experience at BMS and J&J, has been appointed as Director for Institutional Business & Public Channels. These strategic hires from top-tier global competitors are aimed at driving growth in high-value therapeutic areas and expanding market access.

Ms. Aditi Dayarus Mehta appointed as Director – Oncology Business Unit with 15+ years of leadership experience.
Mr. Nitin Bindal appointed as Director - Institutional Business & Public Channels with 17+ years of industry expertise.
Both appointments are effective from January 12, 2026, following Board and NRC approval.
New leaders bring specialized experience from global giants including Pfizer, Bristol Myers Squibb, and Johnson & Johnson.

💡 Investors should view these high-caliber hires as a positive step toward strengthening the company's core oncology and institutional segments. Monitor the execution of new strategies in these divisions over the coming fiscal year.

View All ASTRAZEN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 29% YoY to INR 1,300 Cr. Product sales crossed INR 1,000 Cr for the first time. Q1 FY25 revenue grew 45% YoY excluding Lynparza, and 8% on a quarter-on-quarter basis.

Geographic Revenue Split

Primarily focused on the Indian pharmaceutical market, which is valued at INR 2,16,091 Cr (USD 26.04 billion). Specific % split between domestic and overseas markets not disclosed.

Profitability Margins

Gross margins have declined in the last two quarters of FY24 and Q1 FY25. This is attributed to a shift toward becoming a specialist organization focusing on trading products (imported from parent entities) rather than local manufacturing.

EBITDA Margin

Core profitability metrics not explicitly disclosed, but EPS grew 63% YoY to INR 64.60.

Capital Expenditure

Not disclosed in available documents, though the company is exiting its Bangalore manufacturing site, resulting in a Q1 FY25 write-off of INR 57 Cr.

⚙️ Operational Drivers

Raw Materials

Traded goods and raw materials for pharmaceutical formulations in Oncology, Cardiovascular, Diabetes, and Respiratory therapies.

Import Sources

United Kingdom and Sweden.

Key Suppliers

AstraZeneca UK Limited (INR 831.08 Cr in purchases) and AstraZeneca AB, Sweden (INR 295.28 Cr in purchases).

Capacity Expansion

The company is currently exiting its Bangalore manufacturing site as part of a strategic review of its Global Manufacturing and Supply Network and is exploring a buyer for the site.

Raw Material Costs

Total related party purchases of raw materials and traded goods amounted to approximately INR 1,126.36 Cr in FY25. Procurement is conducted at arm's length.

Manufacturing Efficiency

Maintained zero Lost Time Injuries (LTI) and seamless supply to patients despite the planned exit from the Bangalore facility.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Strategy focused on 'Growth through Innovation' by bringing innovative medicines faster to India and improving patient access. This includes 9 regulatory approvals in FY24 and a strategic alliance with Sun Pharma to leverage their chronic therapy coverage.

Products & Services

Medicines for Oncology, Cardiovascular, Renal, Metabolism (CVRM), Diabetes, Respiratory, and Rare Diseases.

Brand Portfolio

Tagrisso, Imfinzi, Brilinta, Lynparza, Forxiga, Crestor, Enhertu, Seloken XL, Zoladex 10.8, Betaloc, Fasenra, Xigduo, Symbicort.

New Products/Services

9 regulatory approvals achieved in FY24; ongoing focus on the global pipeline to reach parent company's USD 80 billion target by 2030.

Market Expansion

Expanding reach in India through a strategic alliance with Sun Pharmaceutical Industries Limited to leverage their strong presence in chronic therapies.

Market Share & Ranking

Among the top 10 fastest-growing pharma companies in India; improved 3 ranks in FY24.

Strategic Alliances

Sun Pharmaceutical Industries Limited (distribution/reach), Mankind Pharma (recognition of deferred revenue/amortization).

🌍 External Factors

Industry Trends

Indian pharma market grew 7.6% to INR 2,16,091 Cr. MNCs grew 6.05% while Indian companies grew 7.9%. The market is largely out-of-pocket and fragmented.

Competitive Landscape

Highly competitive and fragmented; Indian companies hold an 83% market share by value.

Competitive Moat

Moat is built on a strong innovation pipeline from the parent company and a leading position in high-growth segments like Oncology (Tagrisso sales of INR 319.9 Cr).